At the news
? MIXEDIMPACT 6/10 PRESS-RELEASE filed Aug 13, 2026 at 07:30 ET
MiNK Therapeutics reported Q2 2026 net loss of $3.1M ($0.62/share), improving from $4.2M ($1.06/share) in Q2 2025, with cash burn slowing to $8.8M from $9.5M. The key catalyst is the randomized Phase 2 trial of agenT-797 in acute lung injury showing early positive Day 28 signals, plus the first paid named-patient access program in Brazil establishing a potential revenue stream.
- Q2 2026 net loss $3.1M ($0.62/share) vs $4.2M ($1.06/share) in Q2 2025
- Cash and equivalents $8.8M as of June 30, 2026, down from $9.5M at March 31, 2026
- First patients in randomized Phase 2 trial C-1300-02 alive at Day 28 with improved oxygenation and reduced inflammatory markers
- Launched paid named-patient access program in Brazil for agenT-797, potentially generating program revenue
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access